ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ARNA Stock Price » ARNA Stock News

Arena Share News

 Arena Pharmaceuticals (mm) Stock Price
ARNA Stock Price
 Arena Pharmaceuticals (mm) Stock Chart
ARNA Stock Chart
 Arena Pharmaceuticals (mm) Stock News
ARNA Stock News
 Arena Pharmaceuticals (mm) Company Information
ARNA Company Information
 Arena Pharmaceuticals (mm) Stock Trades
ARNA Stock Trades

Arena, Eisai Diet Drug Less Concentrated In Human Brain Than Rat

By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK -(Dow Jones)- Arena Pharmaceuticals Inc. (ARNA) and Eisai Co. (ESALY, 4523.TO) said that a study of the diet pill lorcaserin showed that the drug seems to concentrate in the human brain less than it does in rats. The data is part of the companies' work to respond to Food and Drug Administration concerns that led to the pill being rejected for approval last year. The agency requested multiple sets of new data including studies related to breast cancer and brain cancer occurring in rats, and more information on heart-related risk. The company said that the effort to address other FDA concerns is ongoing. Arena conducted the study by measuring lorcaserin concentrations in human cerebrospinal fluid and then seeing how that compared to the amount of the drug in blood plasma. The company used an "apparent consistent relationship" of the amount of lorcaserin in the brain in relation to the spinal fluid of mice, rats and monkeys. That ratio was used to predict the corresponding amount of the drug in the human brain using the spinal fluid measurements. Using the new data and previous information, Arena estimates that human brain exposure to the drug is 1.7 times the plasma concentration at normal dose. In rats with a much higher dose, but which didn't have brain cancer, the ratio was 24 times. Arena noted that its estimates in the study are based on "certain assumptions and extrapolations" and the FDA may have different findings when looking at the raw data. The agency also may not view the company estimates as "reliable or predictive of the safety margin," Arena said in a statement. -By Thomas Gryta, Dow Jones Newswires; 212-416-2169;

Stock News for Arena (ARNA)
11/24/201508:00:00Arena Pharmaceuticals to Present at Piper Jaffray 27th Annual...
11/19/201508:00:00Arena Pharmaceuticals to Host Analyst & Investor Day on December...
11/12/201511:00:033 Dangerous Stocks
11/10/201516:20:28Current Report Filing (8-k)
11/10/201516:00:00Arena Pharmaceuticals Reports Third Quarter 2015 Financial Results...
11/09/201516:53:33Quarterly Report (10-q)
11/06/201512:20:29Why Orexigen Therapeutics, Inc.'s Stock Is Losing Weight Today
11/04/201508:00:00Arena Pharmaceuticals to Host Third Quarter 2015 Financial Results...
11/02/201508:00:00Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin...
11/02/201507:04:023 Things You Never Knew About Medicare
10/30/201512:25:20Here's Why Arena Pharmaceuticals, Inc. Is Struggling Today
10/29/201516:36:00Current Report Filing (8-k)
10/29/201508:00:00Arena Pharmaceuticals Initiates a Phase 1b Clinical Trial of...
10/27/201516:14:37Current Report Filing (8-k)
10/27/201516:00:00Arena Pharmaceuticals Announces New Strategic Focus and Cost...
10/27/201508:00:00Arena Pharmaceuticals Issued Additional Patent Covering BELVIQ®...
10/26/201506:24:42Vivus: Qsymia Takes Second Place This Week- Is It A Sign?
10/26/201506:18:58Orexigen: Contrave Sales Flat- Big Bump In Market Share
10/26/201506:15:38Arena: Belviq Sales Drop To Third Place- Can A Turnaround Happen?
10/19/201515:44:00IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation...

Arena Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations